Annexin Pharmaceuticals
0.297 SEK +2.41%2 investors are following this company
Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ANNX
Daily low / high price
0.275 / 0.32
SEK
Market cap
102.94M SEK
Turnover
112.17K SEK
Volume
397K
Financial calendar
General meeting
2024-05-22
Interim report
2024-07-18
Interim report
2024-10-17
Annual report
2025-02-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mikael Lönn | 25.1 % | 25.1 % |
Arne Andersson | 17.6 % | 17.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns
Annexin Pharmaceuticals AB: BioStock: Annexin towards completion of phase II study and share issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools